TY - JOUR T1 - Oncostability: stability of reconstituted and diluted anticancer medicines for a possible extension of use JF - European Journal of Hospital Pharmacy JO - Eur J Hosp Pharm DO - 10.1136/ejhpharm-2021-003157 SP - ejhpharm-2021-003157 AU - Marco Chiumente AU - Melania Rivano AU - Debora Severino AU - Sara Bertoli AU - Anna Rita Gasbarro AU - Rossella Santeramo AU - Alessandra Pasqualini AU - Riccardo Provasi AU - Daniele Mengato AU - Angelo Claudio Palozzo Y1 - 2021/12/14 UR - http://ejhp.bmj.com/content/early/2021/12/14/ejhpharm-2021-003157.abstract N2 - The chemical-physical stability, reported in the Summary of Product Characteristics (SPC), indicates the time parameters within which the manufacturer guarantees the use of the drug once the vial has been handled (in-use stability).The stability data reported in the SPC are often time limited. An extended time of use of the preparation, without affecting drug stability and safety, would facilitate the organisation of anticancer drug compounding and be economically advantageous due to the possibility of using the residues for subsequent preparations.1 2 A unique source of evidence-based stability data regarding antineoplastic drugs should be a helpful tool for pharmacists. In addition, given the lack of homogeneity in the interpretation of data in the literature, it is necessary to harmonise the methodology … ER -